CClinicalTrials.gg
RecruitingNCT07280104Updated Feb 12, 2026

Infants With Primary Congenital Hypothyroidism and Development

An observational study in Congenital Hypothyroidism, sponsored by Nigde Omer Halisdemir University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 6 Months to 18 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Nigde Omer Halisdemir University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
40
Ages
6 Months to 18 Months
Sex
All
01

Study summary

A review of the literature has focused primarily on the cognitive and motor development of children with congenital hypothyroidism, but no studies on sensory processing skills have been found. Considering the age range of the groups studied, studies conducted in the early stages of life are rare. This planned study aims to examine the neurological status, motor development, and sensory processing skills of infants aged 6-18 months, considering early synaptogenesis.

Read the detailed description

The thyroid gland is responsible for producing the hormones necessary for normal growth and development. Congenital hypothyroidism is a condition characterized by underactive or absent thyroid gland in infants. Because thyroid hormone is essential for brain development, these children are at risk for brain damage and related cognitive and motor deficits. Initiating thyroxine supplementation early after birth through newborn screening programs aims to minimize this brain damage. Various studies on the effectiveness of these screening programs have shown that early thyroxine supplementation results in intelligence quotients within the normal range. However, mild cognitive and motor deficits, such as attention and balance problems, are present in most patients.

This planned study aims to examine the neurological status, motor development, and sensory processing skills in infants aged 6-18 months. The results of this study may provide a scientific basis for early follow-up and intervention programs by demonstrating the potential impact of congenital hypothyroidism on these developmental areas.

02

Conditions studied

  • Congenital Hypothyroidism

Keywords

  • Hypothyroidism
  • neurological status
  • motor development
  • sensory processing
03

Who can participate

Ages eligible
6 Months to 18 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Primary congenital hypothyroidism is an endocrine disorder that develops from birth due to insufficient thyroid hormone production by the thyroid gland. The term "primary" indicates that the problem originates directly from the thyroid gland itself, meaning there is no disorder at the hypothalamus or pituitary level. The study aims to recruit infants with and without primary congenital hypothyroidism (controls) who meet the inclusion criteria and whose parents provide voluntary consent.

Inclusion criteria

  • Those with primary congenital hypothyroidism who have been treated since the newborn period and are currently on treatment.
  • Infants born at term.
  • Between 6 and 18 months old.

Exclusion criteria

Exclusion Criteria:

  • Infants with secondary congenital hypothyroidism,
  • Preterm infants,
  • Those with congenital infections or proven genetic alterations,
  • Infants diagnosed with metabolic, neurological, or genetic diseases,
  • Infants whose parents did not volunteer for the study
04

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • congenital hypothyroidism

    The thyroid gland is responsible for producing hormones necessary for normal growth and development. Congenital hypothyroidism is a condition characterized by an underactive or absent thyroid gland in infants.

    Behavioral: neurological status · Behavioral: sensory processing functions · Behavioral: Motor development

  • Control Group

    A control group of 20 healthy children, born at term and aged between 6 and 18 months, without primary congenital hypothyroidism will be created.

    Behavioral: neurological status · Behavioral: sensory processing functions · Behavioral: Motor development

Interventions

  • Behavioralneurological status

    The Hammersmith Infant Neurological Examination (HINE) was planned to be used to assess the neurological status of infants. The HIND is a standardized examination for children aged 3 to 24 months, with high predictive value in the early detection of neurological disorders.

  • Behavioralsensory processing functions

    The Test of Sensory Function in Infants (TSFI) was planned to be used to assess infant sensory development. The TSFI is frequently used to assess the sensory processing functions of infants aged 4-18

  • BehavioralMotor development

    The Peabody Developmental Motor Scales-2 (PDMS-2) was planned to be used to assess motor development. The test is designed to identify developmental delays in children aged 0-72 months.

05

What researchers measure

Primary outcomes

  1. Motor development

    The Peabody Developmental Motor Scales-2 (PDMS-2) was planned to be used to assess motor development. The test is designed to identify developmental delays in children aged 0-72 months. Separate tests and rating scales are used to assess children's motor development, including both gross and fine motor skills. Each item in the PDMS-2 is scored on a 3-point ordinal scale reflecting the child's performance: 2 points - the child performs the item according to the specified criteria; 1 point - the child's performance shows emerging skill or partial success; 0 points - the child cannot or will not attempt the item, or the attempt does not meet criteria.

    Time frame: 6-18 month

  2. Sensory development

    The Test of Sensory Functions in Infants (TSFI) was planned to be used to assess infant sensory development. The TSFI is frequently used to assess the sensory processing functions of infants aged 4-18 months. It is used to determine whether an infant has a sensory processing problem and to what extent. It consists of 24 items. The TSFI requires the infant to be stimulated and interact with various materials. The total score ranges from 0-49, and the test has normative values for different age groups. Although it is used from the fourth month onward, the most reliable and valid results are obtained between 7-18 months.

    Time frame: 6-18 months

  3. Neurological Examination

    The Hammersmith Infant Neurological Examination (HINE) was planned to be used to assess the neurological status of infants. The HINE is a standardized examination for children aged 3 to 24 months, with high predictive value in the early detection of neurological disorders. It is a standardized clinical assessment tool developed to assess the neurological integrity, nervous system maturity, and potential neuromotor disorders in newborns. The HINE is grouped under three main subheadings: neurological, motor, and behavioral. Each item is scored from 0 to 3. The total score reflects the level of neurological maturity and abnormality. There are 26 items in total, with a maximum score of 78. A higher score indicates a more mature neurological status.

    Time frame: 6-18 months

06

Study locations

1 of 1 sites recruiting
  • Nigde Omer Halisdemir University
    Niğde, Turkey (Türkiye)
    Recruiting
07

References and documents

Publications

  • Naafs JC, Marchal JP, Fliers E, Verkerk PH, Luijten MAJ, Boelen A, van Trotsenburg ASP, Zwaveling-Soonawala N. Cognitive and Motor Outcome in Patients with Early-Detected Central Congenital Hypothyroidism Compared with Siblings. J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1231-e1239. doi: 10.1210/clinem/dgaa901. PubMed 33274354 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT07280104
Lead sponsor
Nigde Omer Halisdemir University
Responsible party
Rabia ZORLULAR (principal investigator, Nigde Omer Halisdemir University) — Principal investigator
First posted
Dec 12, 2025
Start date
Dec 20, 2025
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Feb 12, 2026

Study contacts

Rabia ZORLULAR
Contact
rabiaeraslan118@gmail.com
+5424362082

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion